Acrivon Therapeutics, Inc.

NasdaqGM:ACRV Stock Report

Market Cap: US$74.9m

Acrivon Therapeutics Management

Management criteria checks 2/4

Acrivon Therapeutics' CEO is Peter Blume-Jensen, appointed in Mar 2018, has a tenure of 8.17 years. total yearly compensation is $2.72M, comprised of 26.1% salary and 73.9% bonuses, including company stock and options. directly owns 4.64% of the company’s shares, worth $3.48M. The average tenure of the management team and the board of directors is 4.1 years and 4.4 years respectively.

Key information

Peter Blume-Jensen

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage26.11%
CEO tenure8.2yrs
CEO ownership4.6%
Management average tenure4.1yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Analysis Article • Mar 27

We're Keeping An Eye On Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 15

Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?

NasdaqGM:ACRV 1 Year Share Price vs Fair Value Explore Acrivon Therapeutics's Fair Values from the Community and select...
Analysis Article • Mar 27

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 12

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Summary Acrivon Therapeutics is developing a targeted oncology therapy with a companion proteomics-based signature, showing promising activity in their lead compound for certain patients with gynecologic cancers. The pipeline updates indicate progress in clinical trials, enhancing the potential for successful outcomes in targeted cancer treatments. Financially, Acrivon is well-positioned with sufficient funding to advance its pipeline, though risks remain inherent in biotech investments. The bottom-line summary highlights Acrivon's strengths in innovative therapy development, balanced with the risks typical of early-stage biotech ventures. Read the full article on Seeking Alpha
Analysis Article • Nov 17

We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Sep 18

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Summary Acrivon Therapeutics shows promise in precision oncology with its AP3 platform and positive Phase 2 data for ACR-368, indicating potential for significant stock growth. Acrivon’s robust pipeline, including the accelerated development of ACR-2316, and a strong cash position, highlight its commitment to advancing innovative cancer therapies. Despite being pre-revenue and operating at a loss due to high R&D expenses, ACRV maintains a healthy cash balance, crucial for ongoing operations and development. Analysts project a 163.3% upside, with a target price of $21.67 per share, driven by positive clinical data, pipeline advancements, and strong financial health. Read the full article on Seeking Alpha
Analysis Article • Jul 17

Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 29

Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Oct 05

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 22

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 22

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Peter Blume-Jensen's remuneration changed compared to Acrivon Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$77m

Dec 31 2025US$3mUS$710k

-US$78m

Sep 30 2025n/an/a

-US$82m

Jun 30 2025n/an/a

-US$86m

Mar 31 2025n/an/a

-US$84m

Dec 31 2024US$2mUS$655k

-US$81m

Sep 30 2024n/an/a

-US$77m

Jun 30 2024n/an/a

-US$69m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$6mUS$629k

-US$60m

Sep 30 2023n/an/a

-US$50m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$22mUS$536k

-US$31m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$757kUS$430k

-US$16m

Compensation vs Market: Peter's total compensation ($USD2.72M) is above average for companies of similar size in the US market ($USD627.03K).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.

CEO

Peter Blume-Jensen (62 yo)

8.2yrs
Tenure
US$2,718,538
Compensation

Mr. Peter Blume-Jensen, MD, PhD., is Member of Advisory Board of Bio-AI Health Inc. He served as a Member of Advisory Board at Kernal Biologics, Inc. until February 2025. Mr. Blume-Jensen is the Founder, C...

Leadership Team

NamePositionTenureCompensationOwnership
Peter Blume-Jensen
Co-Founder8.2yrsUS$2.72m4.64%
$ 3.5m
Kristina Masson
Co-Founderno dataUS$1.42m0.72%
$ 541.0k
Eric Devroe
Chief Operating Officer3.8yrsUS$1.36m0.16%
$ 119.6k
Adam Levy
CFO & Principal Financial Officer1.1yrsno data0.032%
$ 24.1k
Katharine Peterson
Vice President of Finance & Accountingno datano data0.0091%
$ 6.8k
Bruce Close
Vice President of Quality & Compliance4.1yrsno datano data
Mary-Alice Miller
Chief Legal Officer & Corporate Secretary3.6yrsUS$697.00k0.056%
$ 42.3k
Erick Gamelin
Chief Development Officer5.2yrsUS$538.08k0.026%
$ 19.3k
Jesper Olsen
Academic Co-Founderno datano datano data
Joon Jung
VP & Head of Data Science4.1yrsno datano data
Thomas Nifong
Head of Clinical CDx Operations4.1yrsno datano data
John Duzer
Senior Vice President of Chemistry Manufacturing & Controlsno datano datano data
4.1yrs
Average Tenure
55yo
Average Age

Experienced Management: ACRV's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Blume-Jensen
Co-Founder8.2yrsUS$2.72m4.64%
$ 3.5m
Kristina Masson
Co-Founder8.2yrsUS$1.42m0.72%
$ 541.0k
Jesper Olsen
Academic Co-Founder4.4yrsno datano data
George Demetri
Member of Scientific Advisory Board4.4yrsno datano data
Ivana Magovcevic-Liebisch
Independent Director2.3yrsUS$65.37k0.034%
$ 25.3k
Sharon Shacham
Independent Director5.6yrsUS$65.37k0.12%
$ 90.3k
Michael Tomsicek
Independent Director3.6yrsUS$72.87k0%
$ 0
Charles Baum
Independent Director2.9yrsUS$77.87k0.096%
$ 71.8k
Santhosh Palani
Independent Director2.2yrsUS$118.31k0.032%
$ 23.7k
Derek DiRocco
Independent Director4.5yrsUS$70.37k0.12%
$ 90.3k
Timothy A. Yap
Member of Scientific Advisory Board4.4yrsno datano data
David Berman
Member of Advisory Board4.4yrsno datano data
4.4yrs
Average Tenure
56.5yo
Average Age

Experienced Board: ACRV's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 17:50
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acrivon Therapeutics, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li Wang WatsekCantor Fitzgerald & Co.
Silvan TuerkcanCitizens JMP Securities, LLC
Emily BodnarH.C. Wainwright & Co.